Shire pleased with Vyvanse growth
Nov. 12 - Specialty drug maker Shire says the refill rate for it's Vyvanse drug used to treat ADHD is "better than 90-percent" as it enters its 18th week on the market.
Shire's CEO Matthew Emmens, speaking at the Reuters Health Summit in New York on Monday, says Vyvanse already has 5 1/2-percent market share and analysts expect it to continue to add 1-percent market share a month. Emmens says the new drug is generating about forty thousand prescriptions a week. SPEAKER: Matthew Emmens, CEO, Shire
No videos currently selected.
Click 
on any video below, from any channel, to add it to your playlist.
Marilyn Monroe "smoking pot"
Featured Videos
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
